Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Indiana University study reveals connection between mussels and muscles

Indiana University study reveals connection between mussels and muscles

Teen girls from rural areas have undiagnosed asthma, face higher risk of depression

Teen girls from rural areas have undiagnosed asthma, face higher risk of depression

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Study shows link between autoimmune diseases and gene regulatory elements

Study shows link between autoimmune diseases and gene regulatory elements

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Mercury associated with autoimmunity among women of childbearing age

Mercury associated with autoimmunity among women of childbearing age

New study shows that chronic narcotic use more prevalent in children with IBD

New study shows that chronic narcotic use more prevalent in children with IBD

Study identifies genetic basis of drug toxicity in leukemia patients of East Asian ancestry

Study identifies genetic basis of drug toxicity in leukemia patients of East Asian ancestry

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

Steroid use associated with five-fold increase of blood clots in IBD patients

Steroid use associated with five-fold increase of blood clots in IBD patients

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

New study links inflammatory bowel diseases to increase in diversity of viruses

New study links inflammatory bowel diseases to increase in diversity of viruses

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

British scientists take major initiative to tackle Crohn's disease

British scientists take major initiative to tackle Crohn's disease

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

TxCell announces further enhancement to development of Ovasave for IBD treatment

TxCell announces further enhancement to development of Ovasave for IBD treatment

New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

Researchers remake brain and gut stem cells to study potential therapies for fatal diseases

Researchers remake brain and gut stem cells to study potential therapies for fatal diseases

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.